Physician profile
Susan E Given
NPI 1649496472
$2,173.13
in general payments reported to CMS, 2019-2025
25 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $511 · 2023: $851 · 2024: $340 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $322.35 | 2022-2024 | |
| Edwards Lifesciences Corporation | $212.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $201.09 | 2022-2025 | Camzyos |
| Amgen INC. | $174.95 | 2022-2025 | Repatha, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.12 | 2023-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $132.39 | 2022-2023 | Evkeeza, Praluent |
| Alnylam Pharmaceuticals INC. | $123.67 | 2023-2025 | Amvuttra |
| Cvrx, INC. | $120.65 | 2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $105.98 | 2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $91.70 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, Ltd. | $81.01 | 2022-2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $55.19 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $52.91 | 2023-2025 | Farxiga, Wainua |
| Abiomed | $44.96 | 2025 | |
| Heartflow, INC. | $44.80 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.49 | 2023-2024 | Lifevest |
| Shockwave Medical, INC | $34.24 | 2025 | |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Daiichi Sankyo INC. | $29.31 | 2023 | Injectafer |
| Recor Medical INC | $20.76 | 2024 | Paradise Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $20.34 | 2024 | Opsumit, Uptravi |
| Amryt Pharma Holdings Ltd | $19.86 | 2022 | |
| Boston Scientific Corporation | $17.09 | 2024 | |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Given listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.